Latest PILA PHARMA News & Updates

See the latest news and media coverage for PILA PHARMA. We track all announcements, press releases, and industry mentions in real time, all in one place.

PILA PHARMA

Clinical-stage biotech developing oral TRPV1 therapies for obesity and diabetes

pilapharma.com

Headquarters: Malmö, Sweden
Founded year: 2014
Company type: Public company
Number of employees: 5–10
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about PILA PHARMA

In short: PILA PHARMA advanced its obesity drug candidate XEN-D0501 into mid-stage trials and secured SEK 5.4 million through warrant exercises.

Company announcements

September 2 PILA PHARMA

PILA PHARMA advances obesity pipeline with new trial approval

The company shares regulatory clearance for extended clinical studies of its oral TRPV1 antagonist and releases a H1 financial report recap featuring CEO insights on safety data.

August 18 PILA PHARMA

PILA PHARMA receives regulatory approval to conduct PP-CT04 trial for XEN-D0501

The phase 1 study evaluates the safety and efficacy of the oral TRPV1 antagonist in obese participants over 12 weeks.

July 31 PILA PHARMA

PILA PHARMA reports share transfer between controlled companies on July 27 2026

Chairman Dorte X. Gram consolidated holdings via an agreement at SEK 1.18 per share while retaining a 13.8% stake in the biotech firm.

May 22 PILA PHARMA

PILA PHARMA holds annual general meeting resolutions

The company elected new board members, authorized share issuance for financing and acquisitions, and appointed Deloitte as auditor.

Media coverage

September 1 ZoneBourse

Pila Pharma is moving towards higher dosages - BioStock

The biotechnology company Pila Pharma has recently received regulatory approval to launch the PP-CT04 study on its TRPV1 antagonist for obesity and other ...

July 30 ZoneBourse

The chairman of Pila Pharma acquires shares for nearly 6 million crowns

Dorte Gram, chairman of the board of the biotechnology company Pila Pharma, acquired 5,000,010 shares of the company on the 27th...

April 16 FinanzNachrichten.de

Pila Pharma AB: Update To Preclinical Rat Obesity Studies - Low Exposure Of Xen-d0501 Could Explain Lack Of Effect On Bodyweight

PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announces that drug...

March 21 Placera.se

Pila Pharma postpones annual report and AGM (update) | Placera.se

Following inquiries from shareholders, Pila Pharma clarifies that the postponement is not linked to the company's financial position or any complications in the audit process.

Never miss news about PILA PHARMA

Track PILA PHARMA and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.